US 12,077,824 B2
Salivary extracellular RNA biomarkers for gingivitis
David T. W. Wong, Beverly Hills, CA (US); Karolina Elzbieta Kaczor-Urbanowicz, Los Angeles, CA (US); Harsh Mahendra Trivedi, Hillsborough, NJ (US); and James Masters, Ringoes, NJ (US)
Assigned to Colgate-Palmolive Company, New York, NY (US); and The Regents of the University of California, Oakland, CA (US)
Filed by Colgate-Palmolive Company, New York, NY (US); and The Regents of the University of California, Oakland, CA (US)
Filed on Sep. 10, 2021, as Appl. No. 17/471,876.
Application 17/471,876 is a continuation of application No. 16/171,418, filed on Oct. 26, 2018, granted, now 11,124,833.
Claims priority of provisional application 62/577,887, filed on Oct. 27, 2017.
Prior Publication US 2021/0404005 A1, Dec. 30, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6883 (2018.01)
CPC C12Q 1/6883 (2013.01) [C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01)] 7 Claims
 
1. A method of treating gingivitis in a subject in need thereof, comprising:
a. obtaining a saliva sample of a subject;
b. detecting in the saliva sample the level of at least one biomarker selected from the group consisting of NONHSAT006501.2, NONHSAT071649, NONHSAT005224, LGALS3, AF156166, SOX4, FAM25A, AL832615, SLPI, and CRCT1;
wherein the subject is identified as being in need of treatment when the level of the at least one biomarker in the saliva sample of subject is differentially expressed when compared with the level of the biomarker in a comparator control, thereby diagnosing gingivitis in the subject;
wherein the differentially expressed level of at least one biomarker selected from the group consisting of NONHSAT071649, NONHSAT005224, AF156166, and SOX4 is increased as compared to the level of the at least one biomarker in the comparator control;
wherein the differentially expressed level of at least one biomarker selected from the group consisting of NONHSAT006501.2, LGALS3, FAM25A, and CRCT1 is decreased as compared to the level of the at least one biomarker in the comparator control; and
wherein the level of the at least one biomarker in the saliva sample is determined by measuring the level of nucleic acid of the at least one biomarker; and
c. treating the subject for gingivitis, consequent to the detection in step b;
 wherein said treating comprises one or more of dental procedures, periodontal procedures, surgical procedures, administration of pharmaceuticals, therapeutics or prophylactics; professional dental cleaning; scaling and root planning; dental restoration, use of chlorohexidine rinses; oral irrigation, interdental brushing, use of toothpastes containing Stannous, Zinc, Triclosan, and/or hydrogen peroxide; use of mouthwashes containing Triclosan, Cetylpyridinium chloride, other quaternary ammonium chlorides and/or essential oils.